A series of N-acylprolyltyrosine amides was designed as tripeptoid analogues of neurotensin. The substituted dipeptides were tested in vivo for antidopamine activity by their ability to inhibit the apomorphine-induced climbing in mice and the dopamine-induced extrapolatory behavior impairment in rats. The N-acylprolyltyrosine amides structure-activity relationships have indicated the size of the N-acyl group and the configuration of amino acids that are important for the activity. We found that the bioactivity has been increased dramatically when the n-hydrocarbon chain on the N-acyl group was increased from four to five carbon atoms. The activity seems to reside exclusively in the L-Tyr diastereomers. All of the compounds tested were inactive in the cataleptogenic action and did not exhibit the acute toxicity even at doses 500-1000 times higher than ED50 in climbing test. On this basis, the N-acylprolyltyrosine amides could potentially be a novel class of atypical antipsychotic agents.
Stereoselectivity of the Antidopaminergic Effect of the Methyl Ester of N-Caproylprolyltyrosine (I) -a Tripeptide Analogue of Neurotensin.-It is shown, that for an optimal antidopaminergic effect both amino acid residues of the title N-caproylprolyltyrosine (I) must have L-configuration. Changing one of the amino acids by its D-enantiomer results in loss of activity. N-Caproylprolyltyrosine containing D-prolyl and D-tyrosyl residues has a "pro-dopamine" effect. -(ZAITSEVA, N. I.; GUBASHEVA, T. A.; BRILING, V. K.; GUZEVATYKH, L. S.; OSTROVSKAYA, R. U.; VORONINA, T. A.; SEREDENIN, S. B.; Khim.-Farm. Zh. 34 (2000) 8, 20-22; Nauchno-issled. inst. farmakol. Ross. Akad. med. nauk, Moskva 125315, Russia; RU)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.